.png){kind=logo}
™
Accurate diagnostics with precision biomarkers
Genetic biomarkers are particularly useful for diagnoses and therapeutics. However, most approved drugs have a single variant biomarker. Heligenics offers whole gene biomarkers, where diagnosis can be based upon all variants with similar activity to an established biomarker.
​
Whole gene biomarkers examine all the mutations in a gene rather than a single mutation. This is a natural conceptual expansion of what is already in common clinical practice.
Five Facts
-
Steady growth in genetic biomarkers over the last decade
-
There are 100s of genetic biomarkers
-
Genes have many variants with the same activity as known biomarkers
-
Whole gene biomarkers expand the number of customers eligible for a drug
-
Drug resistance mutations for a whole gene are useful
Why use one genotype when you can use a whole gene biomarker?
Treatments based on one genetic marker have medical advantages
-
46% of total recent approvals
-
One mutation as a biomarker
From “The Personalized Medicine Report: 2017 Opportunity, Challenges, and the Future”.
http://www.personalizedmedicinecoalition.org
One Size Does Not Fit All
Percentage of the patient population for which a particular drug is NOT effective
Anti-Depressants (SSRIs) 38%
Asthma Drugs 40%
Diabetes Drugs 43%
Arthritis Drugs 50%
Alsheimer’s Drugs 70%
Cancer Drugs 75%
Whole Gene Biomarker
Example of patients with single mutation biomarker identified versus using MEGA-Map™ whole gene biomarker panel
Single Mutation
Biomarker
MEGA-Map™ Whole Gene Biomarker
Disease, but lack Single
Mutation Biomarker
Disease with Whole Gene
Biomarker
Disease with Single Mutation
Biomarker